Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy
Mengying Tang, Jing Liu · 2026
Read Autocrine Control of CD276 by SPARC in Liver Cancer and Its Contribution to Immune Escape and Resistance to Immunotherapy by Mengying Tang, Jing Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13512768.txt.
Description
Mengying Tang and Jing Liu trace how a tumor protein helps liver cancer hide from the immune system. Hepatocellular carcinoma often resists immunotherapy, and escape routes run through the tumor's local setting. The protein SPARC, shed by cells into that setting, has been tied to cancer growth in many organs.
In their 2026 study, a mouse liver tumor line was tuned to make more or less SPARC and CD276, a checkpoint shield. Extra SPARC raised CD276 through a p65 and c-Myc path and fed cancer stemness. Tumors then let fewer killer T cells in, and checkpoint drugs worked worse. The work names a self-feeding loop that tumors use to blunt immune attack.
Catalog record
| CREATOR | Mengying Tang, Jing Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |